Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Chloroplast Outer Membrane β-Barrel Proteins Use Components of the General Import Apparatus.

Day PM, Inoue K, Theg SM.

Plant Cell. 2019 Aug;31(8):1845-1855. doi: 10.1105/tpc.19.00001. Epub 2019 Jun 19.

PMID:
31217220
2.

Human Papillomavirus 16 Capsids Mediate Nuclear Entry during Infection.

Day PM, Weisberg AS, Thompson CD, Hughes MM, Pang YY, Lowy DR, Schiller JT.

J Virol. 2019 Jul 17;93(15). pii: e00454-19. doi: 10.1128/JVI.00454-19. Print 2019 Aug 1.

PMID:
31092566
3.

A Prime-Pull-Amplify Vaccination Strategy To Maximize Induction of Circulating and Genital-Resident Intraepithelial CD8+ Memory T Cells.

Çuburu N, Kim R, Guittard GC, Thompson CD, Day PM, Hamm DE, Pang YS, Graham BS, Lowy DR, Schiller JT.

J Immunol. 2019 Feb 15;202(4):1250-1264. doi: 10.4049/jimmunol.1800219. Epub 2019 Jan 11.

PMID:
30635393
4.

Evolution of protein transport to the chloroplast envelope membranes.

Day PM, Theg SM.

Photosynth Res. 2018 Dec;138(3):315-326. doi: 10.1007/s11120-018-0540-x. Epub 2018 Oct 5. Review.

PMID:
30291507
5.

Efficient Production of Papillomavirus Gene Delivery Vectors in Defined In Vitro Reactions.

Cerqueira C, Thompson CD, Day PM, Pang YS, Lowy DR, Schiller JT.

Mol Ther Methods Clin Dev. 2017 Apr 19;5:165-179. doi: 10.1016/j.omtm.2017.04.005. eCollection 2017 Jun 16.

6.

Interferon Gamma Prevents Infectious Entry of Human Papillomavirus 16 via an L2-Dependent Mechanism.

Day PM, Thompson CD, Lowy DR, Schiller JT.

J Virol. 2017 Apr 28;91(10). pii: e00168-17. doi: 10.1128/JVI.00168-17. Print 2017 May 15.

7.

Involvement of Nucleophosmin (NPM1/B23) in Assembly of Infectious HPV16 Capsids.

Day PM, Thompson CD, Pang YY, Lowy DR, Schiller JT.

Papillomavirus Res. 2015 Dec;1:74-89. Epub 2015 Jun 25.

8.

MSH1 Is a Plant Organellar DNA Binding and Thylakoid Protein under Precise Spatial Regulation to Alter Development.

Virdi KS, Wamboldt Y, Kundariya H, Laurie JD, Keren I, Kumar KRS, Block A, Basset G, Luebker S, Elowsky C, Day PM, Roose JL, Bricker TM, Elthon T, Mackenzie SA.

Mol Plant. 2016 Feb 1;9(2):245-260. doi: 10.1016/j.molp.2015.10.011. Epub 2015 Nov 14.

9.

A Cell-Free Assembly System for Generating Infectious Human Papillomavirus 16 Capsids Implicates a Size Discrimination Mechanism for Preferential Viral Genome Packaging.

Cerqueira C, Pang YY, Day PM, Thompson CD, Buck CB, Lowy DR, Schiller JT.

J Virol. 2015 Nov 11;90(2):1096-107. doi: 10.1128/JVI.02497-15. Print 2016 Jan 15.

10.

The HPV16 and MusPV1 papillomaviruses initially interact with distinct host components on the basement membrane.

Day PM, Thompson CD, Lowy DR, Schiller JT.

Virology. 2015 Jul;481:79-94. doi: 10.1016/j.virol.2015.02.021. Epub 2015 Mar 12.

11.

Evolution and targeting of Omp85 homologs in the chloroplast outer envelope membrane.

Day PM, Potter D, Inoue K.

Front Plant Sci. 2014 Oct 13;5:535. doi: 10.3389/fpls.2014.00535. eCollection 2014.

12.

Mouse model of cervicovaginal papillomavirus infection.

Çuburu N, Cerio RJ, Thompson CD, Day PM.

Methods Mol Biol. 2015;1249:365-79. doi: 10.1007/978-1-4939-2013-6_27.

PMID:
25348320
13.

Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1.

Handisurya A, Day PM, Thompson CD, Bonelli M, Lowy DR, Schiller JT.

PLoS Pathog. 2014 Aug 14;10(8):e1004314. doi: 10.1371/journal.ppat.1004314. eCollection 2014 Aug.

14.

Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.

Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.

PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.

15.

Large scale RNAi reveals the requirement of nuclear envelope breakdown for nuclear import of human papillomaviruses.

Aydin I, Weber S, Snijder B, Samperio Ventayol P, Kühbacher A, Becker M, Day PM, Schiller JT, Kann M, Pelkmans L, Helenius A, Schelhaas M.

PLoS Pathog. 2014 May 29;10(5):e1004162. doi: 10.1371/journal.ppat.1004162. eCollection 2014 May.

16.

Low doses of flagellin-L2 multimer vaccines protect against challenge with diverse papillomavirus genotypes.

Kalnin K, Tibbitts T, Yan Y, Stegalkina S, Shen L, Costa V, Sabharwal R, Anderson SF, Day PM, Christensen N, Schiller JT, Jagu S, Roden RB, Almond J, Kleanthous H.

Vaccine. 2014 Jun 12;32(28):3540-7. doi: 10.1016/j.vaccine.2014.04.032. Epub 2014 Apr 26.

17.

Concepts of papillomavirus entry into host cells.

Day PM, Schelhaas M.

Curr Opin Virol. 2014 Feb;4:24-31. doi: 10.1016/j.coviro.2013.11.002. Epub 2013 Dec 14. Review.

18.

Characterization of Mus musculus papillomavirus 1 infection in situ reveals an unusual pattern of late gene expression and capsid protein localization.

Handisurya A, Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT.

J Virol. 2013 Dec;87(24):13214-25. doi: 10.1128/JVI.02162-13. Epub 2013 Sep 25.

19.

The papillomavirus major capsid protein L1.

Buck CB, Day PM, Trus BL.

Virology. 2013 Oct;445(1-2):169-74. doi: 10.1016/j.virol.2013.05.038. Epub 2013 Jun 22. Review.

20.

Identification of a role for the trans-Golgi network in human papillomavirus 16 pseudovirus infection.

Day PM, Thompson CD, Schowalter RM, Lowy DR, Schiller JT.

J Virol. 2013 Apr;87(7):3862-70. doi: 10.1128/JVI.03222-12. Epub 2013 Jan 23.

21.

Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses.

Çuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, Lowy DR, Schiller JT.

J Clin Invest. 2012 Dec;122(12):4606-20. doi: 10.1172/JCI63287. Epub 2012 Nov 12.

22.

Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.

Handisurya A, Day PM, Thompson CD, Buck CB, Kwak K, Roden RB, Lowy DR, Schiller JT.

Virology. 2012 Nov 25;433(2):385-94. doi: 10.1016/j.virol.2012.08.035. Epub 2012 Sep 15.

23.

A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Day PM, Pang YY, Kines RC, Thompson CD, Lowy DR, Schiller JT.

Clin Vaccine Immunol. 2012 Jul;19(7):1075-82. doi: 10.1128/CVI.00139-12. Epub 2012 May 16.

24.

Entry of human papillomavirus type 16 by actin-dependent, clathrin- and lipid raft-independent endocytosis.

Schelhaas M, Shah B, Holzer M, Blattmann P, Kühling L, Day PM, Schiller JT, Helenius A.

PLoS Pathog. 2012;8(4):e1002657. doi: 10.1371/journal.ppat.1002657. Epub 2012 Apr 19.

25.

In vivo mechanisms of vaccine-induced protection against HPV infection.

Day PM, Kines RC, Thompson CD, Jagu S, Roden RB, Lowy DR, Schiller JT.

Cell Host Microbe. 2010 Sep 16;8(3):260-70. doi: 10.1016/j.chom.2010.08.003.

26.

Papillomavirus infection requires gamma secretase.

Karanam B, Peng S, Li T, Buck C, Day PM, Roden RB.

J Virol. 2010 Oct;84(20):10661-70. doi: 10.1128/JVI.01081-10. Epub 2010 Aug 11.

27.

Current understanding of the mechanism of HPV infection.

Schiller JT, Day PM, Kines RC.

Gynecol Oncol. 2010 Jun;118(1 Suppl):S12-7. doi: 10.1016/j.ygyno.2010.04.004. Review.

28.

E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases.

Asnaghi L, Vass WC, Quadri R, Day PM, Qian X, Braverman R, Papageorge AG, Lowy DR.

Oncogene. 2010 May 13;29(19):2760-71. doi: 10.1038/onc.2010.39. Epub 2010 Mar 15.

29.

The role of furin in papillomavirus infection.

Day PM, Schiller JT.

Future Microbiol. 2009 Dec;4(10):1255-62. doi: 10.2217/fmb.09.86. Review.

30.

The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding.

Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM.

Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20458-63. doi: 10.1073/pnas.0908502106. Epub 2009 Nov 17.

31.

Role of L2 cysteines in papillomavirus infection and neutralization.

Gambhira R, Jagu S, Karanam B, Day PM, Roden R.

Virol J. 2009 Oct 27;6:176. doi: 10.1186/1743-422X-6-176.

32.

Structure, attachment and entry of polyoma- and papillomaviruses.

Sapp M, Day PM.

Virology. 2009 Feb 20;384(2):400-9. doi: 10.1016/j.virol.2008.12.022. Epub 2009 Jan 21. Review.

33.

Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.

Johnson KM, Kines RC, Roberts JN, Lowy DR, Schiller JT, Day PM.

J Virol. 2009 Mar;83(5):2067-74. doi: 10.1128/JVI.02190-08. Epub 2008 Dec 10.

34.

Heparan sulfate-independent cell binding and infection with furin-precleaved papillomavirus capsids.

Day PM, Lowy DR, Schiller JT.

J Virol. 2008 Dec;82(24):12565-8. doi: 10.1128/JVI.01631-08. Epub 2008 Oct 1.

35.

Human papillomavirus type 16 entry: retrograde cell surface transport along actin-rich protrusions.

Schelhaas M, Ewers H, Rajamäki ML, Day PM, Schiller JT, Helenius A.

PLoS Pathog. 2008 Sep 5;4(9):e1000148. doi: 10.1371/journal.ppat.1000148.

36.

Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.

Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT.

J Virol. 2008 May;82(9):4638-46. doi: 10.1128/JVI.00143-08. Epub 2008 Feb 27.

37.

Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition.

Day PM, Thompson CD, Buck CB, Pang YY, Lowy DR, Schiller JT.

J Virol. 2007 Aug;81(16):8784-92. Epub 2007 Jun 6.

38.

Human alpha-defensins block papillomavirus infection.

Buck CB, Day PM, Thompson CD, Lubkowski J, Lu W, Lowy DR, Schiller JT.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1516-21. Epub 2006 Jan 23.

39.

Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection.

Richards RM, Lowy DR, Schiller JT, Day PM.

Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1522-7. Epub 2006 Jan 23.

40.

A membrane-destabilizing peptide in capsid protein L2 is required for egress of papillomavirus genomes from endosomes.

Kämper N, Day PM, Nowak T, Selinka HC, Florin L, Bolscher J, Hilbig L, Schiller JT, Sapp M.

J Virol. 2006 Jan;80(2):759-68.

41.

Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.

Day PM, Baker CC, Lowy DR, Schiller JT.

Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14252-7. Epub 2004 Sep 21.

42.

Interaction of papillomavirus virus-like particles with human myeloid antigen-presenting cells.

Lenz P, Thompson CD, Day PM, Bacot SM, Lowy DR, Schiller JT.

Clin Immunol. 2003 Mar;106(3):231-7.

PMID:
12706410
43.

Papillomaviruses infect cells via a clathrin-dependent pathway.

Day PM, Lowy DR, Schiller JT.

Virology. 2003 Mar 1;307(1):1-11.

44.

Cell surface-binding motifs of L2 that facilitate papillomavirus infection.

Yang R, Day PM, Yutzy WH 4th, Lin KY, Hung CF, Roden RB.

J Virol. 2003 Mar;77(6):3531-41.

45.

A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy.

Young PJ, Day PM, Zhou J, Androphy EJ, Morris GE, Lorson CL.

J Biol Chem. 2002 Jan 25;277(4):2852-9. Epub 2001 Nov 9.

46.

Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection.

Roden RB, Day PM, Bronzo BK, Yutzy WH 4th, Yang Y, Lowy DR, Schiller JT.

J Virol. 2001 Nov;75(21):10493-7.

47.

Papillomavirus-like particles induce acute activation of dendritic cells.

Lenz P, Day PM, Pang YY, Frye SA, Jensen PN, Lowy DR, Schiller JT.

J Immunol. 2001 May 1;166(9):5346-55.

48.

L1 interaction domains of papillomavirus l2 necessary for viral genome encapsidation.

Okun MM, Day PM, Greenstone HL, Booy FP, Lowy DR, Schiller JT, Roden RB.

J Virol. 2001 May;75(9):4332-42.

49.

A novel member of the BTB/POZ family, PATZ, associates with the RNF4 RING finger protein and acts as a transcriptional repressor.

Fedele M, Benvenuto G, Pero R, Majello B, Battista S, Lembo F, Vollono E, Day PM, Santoro M, Lania L, Bruni CB, Fusco A, Chiariotti L.

J Biol Chem. 2000 Mar 17;275(11):7894-901.

50.

Intracellular localization of proteasomal degradation of a viral antigen.

Antón LC, Schubert U, Bacík I, Princiotta MF, Wearsch PA, Gibbs J, Day PM, Realini C, Rechsteiner MC, Bennink JR, Yewdell JW.

J Cell Biol. 1999 Jul 12;146(1):113-24.

Supplemental Content

Support Center